Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks